Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | RGS12 | O14924 | 3/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.98 |
| ▸ | THPO | P40225 | 3/20 | 0.98 |
| ▸ | MTOR | P42345 | 3/20 | 0.98 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1325230 | 1.00 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL1325958 | 0.99 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL29380552 | 0.99 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL1325960 | 0.99 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL10955950 | 0.91 | MAPT (0.85) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL12878037 | 0.89 | DRD1 (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL12284387 | 0.88 | DRD3 (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| SCHEMBL14535819 | 0.88 | DRD3 (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| Bromide SCHEMBL31027963 | 0.86 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD | |
| Bromide SCHEMBL4923294 | 0.86 | MAPT (1.00) | MAPTMAPK1KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | MAPT 798/4885MAPK1 4354/4885KDM4E 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.